BeVigilant OraFusion System
Granted FDA Breakthrough Device Designation
The BeVigilant™ OraFusion™ System** is Not Available For Sale in the U.S.
The BeVigilant OraFusion System identifies the presence of biomarkers associated with oral cancer in 15 minutes or less.
BeVigilant OraFusion System
With the BeVigilant OraFusion System, clinicians can get a simple and accurate assessment to aid in the early detection of oral cancer. The platform enhances the identification and screening of oral abnormalities by lateral flow immunoassays that detect two salivary biomarkers with clinical risk factors to generate a screening result of “Monitor” or “Further Investigate” results. This suggests the necessity or not for a specialist referral for oral cancer. Learn how it benefits dentists and their patients:
BeVigilant™ OraFusion™ Test
How the BeVigilant OraFusion System Works
BeVigilant OraFusion System is an easy-to-use, accurate point of care for frontline healthcare clinicians who assess potentially at-risk patients for oral cancer.
The BeVigilant Reader is an advanced immunochromatography reader that captures the test data and provides the results during the patient’s visit.
Created to improve outcomes through earlier intervention, the BeVigilant OraFusion System is
easy to use
A simple, non-invasive saliva test eliminates the need for invasive procedures, offering ease and convenience.
real-time results
Delivering results in just 15 minutes or less, streamlining next steps and treatment decisions.
highly accurate
Using multiple biomarkers in conjunction with clinical risk factors provides an accurate risk assessment.
The BeVigilant OraFusion System is patent pending and available in select markets outside the United States. Interested in learning more about the technology’s availability in your market?
Sign me up to learn more.
*Clinical Data on File
EN 
IT 
DE 
TR 
PT 
NL 
FR 
ES